1Q17 public-private partnership roundup


This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year.

Led by Johnson & Johnson’s seven deals, large pharmaceutical companies showed their most active quarter since 2015 and were represented in one quarter of all PPPs.

J&J connected with 26 partners, including 16 through a single deal with the RSV Consortium in Europe (RESCEU).

Among public institutions, three of the top were from the U.K. -- University of Oxford, Imperial College London and Cancer Research UK (CRUK), which each formed two partnerships, including the RESCEU consortium. However, the U.K. will be a region to watch as institutions seek to lay tracks with international organizations in anticipation of possible fallout from Brexit.

The data can be seen in “Public-Private Partnership Highlights” and “Partner Connections,” which contain links to an interactive full version of the data.

Figure: Public-private partnership highlights

An analysis of the top public-private partnership (PPP) dealmakers and their regional locations in 1Q17, plus a quarterly breakdown of PPPs from 2011 to 2017.

Top left: Last quarter, eight companies each formed at least two new partnerships with public institutions, with Johnson & Johnson (NYSE:JNJ) taking the top spot and standing out from the rest with seven. The other companies each formed two partnerships during the period. Top right: In the public sector, nine institutions were involved in at least two partnerships with

Read the full 2419 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers